GlassScriptPhysician profile
Donna Bambach
NPI 1629702568
$2,770.15
in general payments reported to CMS, 2019-2025
22 companies · $826 in 2025
The $826 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $195 · 2023: $940 · 2024: $809 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,575.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $633.17 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $398.28 | 2023-2025 | |
| Lilly USA, LLC | $383.15 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Astellas Pharma US INC | $262.60 | 2023-2025 | Veozah |
| Pfizer INC. | $208.98 | 2022-2025 | |
| Amgen INC. | $183.73 | 2023-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $149.37 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $137.48 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.29 | 2022-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $53.54 | 2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $45.53 | 2024-2025 | Eliquis |
| Glaxosmithkline, LLC. | $37.73 | 2023 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.11 | 2023-2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $28.29 | 2024 | Rexulti |
| Dexcom, INC. | $25.55 | 2024 | Dexcom G6 Transmitter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.84 | 2024 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $20.75 | 2025 | |
| Abbott Laboratories | $20.33 | 2025 | Freestyle Libre 3 |
| Corium, LLC | $19.53 | 2022 | |
| Sumitomo Pharma America, INC. | $15.95 | 2025 | Gemtesa |
| Mylan Specialty L.P. | $15.65 | 2023 | Yupelri |
| Currax Pharmaceuticals LLC | $14.30 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Bambach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.